Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia

References

• Annino L, Vegna ML, Camera A et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863–871.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblasticleukemia. Hematology Am Soc Hematol Educ Program 2006; 133–141.
   PubMedGoogle Scholar
• Thomas X, Boiron JM, Huguet F et al. Outcome of treatment inadults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075–4086.
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. NEngl J Med 2006; 354: 166–178.
   PubMed Web of Science ®Google Scholar
• Marie JP, Huet S, Faussat AM et al. Multicentric evaluation of theMDR phenotype in leukemia. Leukemia 1997; 11: 1086–1094.
   PubMed Web of Science ®Google Scholar
• Norgaard JM, Hokland P. Biology of multiple drug resistance inacute leukemia. Int J Hematol 2000; 72: 290–297.
   PubMed Web of Science ®Google Scholar
• Sonneveld P. Multidrug resistance in haematological malignancies.J Intern Med 2000; 247: 521–534.
   PubMed Web of Science ®Google Scholar
• Knutsen T, Mickley LA, Ried T et al. Cytogenetic and molecularcharacterization of random chromosomal rearrangements activat-ing the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer 1998; 23: 44–54.
   PubMed Web of Science ®Google Scholar
• Marie JP, Zittoun R, Sikic BI. Multidrug resistance (MDR1) geneexpression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–592.
   PubMed Web of Science ®Google Scholar
• Wuchter C, Leonid K, Ruppert V et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000; 85: 711–721.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079.
   PubMed Web of Science ®Google Scholar
• Menssen HD, Siehl JM, Thiel E. Wilms tumor gene (WT1) expression as a panleukemic marker. Int J Hematol 2002; 76: 103–109.
   PubMed Web of Science ®Google Scholar
• Sugiyama H. Wilms tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis. Methods Mol Med 2002; 68: 223–237.
   PubMedGoogle Scholar
• McCoy C, McGee SB, Cornwell MM. The Wilms' tumor suppressor, WT1, inhibits 12-0-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter. Cell Growth Differ 1999; 10: 377–386.
   PubMedGoogle Scholar
• Nagura E, Kimura K, Yamada K et al. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1994; 33: 359–365.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O'Brien S et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxor-ubicin, and dexamethasone (hyper-CVAD), a dose-intensive regi-men, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788–2801.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Smith TL et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547–561.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Cortes J, Giles F et al. Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 2003; 102: 880a.
   Web of Science ®Google Scholar
• Pall G, Spitaler M, Hofmann J, Thaler J, Ludescher C. Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. Leukemia 1997; 11: 1067–1072.
   PubMed Web of Science ®Google Scholar
• Tafuri A, Gregorj C, Petrucci MT et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002; 100: 974–981.
   PubMed Web of Science ®Google Scholar
• Jamroziak K, Mlynarski W, Balcerczak E et al. Functional C3435Tpolymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004; 72: 314–321.
   PubMed Web of Science ®Google Scholar
• Galimberti S, Guerrini F, Carulli G et al. Significant co-expression of WTI and MDR1 genes in acute myeloid leukemia patients at diagnosis. Eur J Haematol 2004; 72: 45–51.
   PubMed Web of Science ®Google Scholar
• Miglino M, Varaldo R, Colombo N et al. Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph + all treated with imatinib containing regimen: preliminary report of two cases. J Exp Clin Cancer Res 2006; 25: 321–324.
   PubMed Web of Science ®Google Scholar
• Boublikova L, Kalinova M, Ryan J et al. Wilms' tumor gene 1 (WTI) expression in childhood acute lymphoblastic leukemia: a wide range of WTI expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006; 20: 254–263.
   PubMed Web of Science ®Google Scholar
• Shareef MM, Brown B, Shajahan S et al. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-KB and NF-Y activation in oral carcinoma cells. Mol Cancer Res 2008; 6: 89–98.
   PubMed Web of Science ®Google Scholar
• Bentires-Alj M, Barbu V, Fillet M et al. NF-KB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22: 90–97.
   PubMed Web of Science ®Google Scholar
• Chen Y, Williams BR. The role of NF-KB in the regulation of the expression of wilms tumor suppressor gene WTI. Gene Expr 2000; 9: 103–114.
   PubMed Web of Science ®Google Scholar
• Shtil AA, Azare J. Redundancy of biological regulation as the basisof emergence of multidrug resistance. Int Rev Cytol 2005; 246: 1–29.
   PubMed Web of Science ®Google Scholar
• Dehbi M, Hiscott J, Pelletier J. Activation of the WTI Wilms' tumor suppressor gene by NF-KB. Oncogene 1998; 16: 2033–2039.
   PubMed Web of Science ®Google Scholar
• Kuo MT, Liu Z, Wei Y et al. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-KB signaling. Oncogene 2002; 21: 1945–1954.
   PubMed Web of Science ®Google Scholar
• Lei HY, Zhao XL. Clinical significance of NF-KB continual activity and expression of WTI and MDR1 in acute nonlympho-cytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007; 15: 253–257.
   PubMedGoogle Scholar
• Bellavia D, Campese AF, Alesse E et al. Constitutive activation of NF-KB and T-cell leukemia/lymphoma in Notch3 transgenic mice. Embo J 2000; 19: 3337–3348.
   PubMed Web of Science ®Google Scholar
• Kirchner D, Duyster J, Ottmann O et al. Mechanisms of BCR-ABL-mediated NF-KB/REL activation. Exp Hematol 2003; 31: 504–511.
   PubMed Web of Science ®Google Scholar
• Vilimas T, Mascarenhas J, Palomero T et al. Targeting the NF-KB signaling pathway in Notchl -induced T-cell leukemia. Nat Med 2007; 13: 70–77.
   PubMed Web of Science ®Google Scholar